Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"

Leo Pharma must create growth and secure a proper pipeline. ”The rest can be figured out if those two things are sorted,” says Peter Haahr, CEO of Leo Pharma’s majority shareholder, the Leo Foundation.
Photo: Leo Pharma/PR
Photo: Leo Pharma/PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Several top managers have been replaced and the organization’s management looks markedly different from just a few years ago. The company is leaking money, and has announced that 1,000 positions are to be terminated.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading